Drugs / RVT-1601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03864328 | Mar 2019 → May 2020 | idiopathic pulmonary fibrosis | Respivant Sciences GmbH | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RVT-1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03864328 ↗ |
| Known as | PA101B | “Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b...” NCT03864328 ↗ |
| Route | Inhaled | “Inhaled RVT-1601 administered TID via eFlow nebulizer” NCT03864328 ↗ |